Author:
Sabe Sharif A.,Xu Cynthia M.,Sabra Mohamed,Harris Dwight D.,Broadwin Mark,Bellam Krishna G.,Banerjee Debolina,Usheva Anny,Abid M. Ruhul,Sellke Frank W.
Funder
NIH
National Heart, Lung, and Blood Institute
Reference22 articles.
1. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019
2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
3. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019
4. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control;Inzucchi;Circulation.,2018
5. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Heidenreich;Circulation.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献